Incanthera Competitors and Similar CompaniesClear all

Incanthera's competitors and similar companies include G1 Therapeutics and Oncolytics Biotech.
Incanthera
Incanthera
Incanthera is a company that engages in the development of novel treatments for solid tumors (cancers).
G1 Therapeutics
G1 Therapeutics
G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer.
Oncolytics Biotech
Oncolytics Biotech
Oncolytics Biotech is a company developing Pelareorep, an intravenously delivered immuno-oncolytic virus, used for the treatment of solid tumors and hematological malignancies.
Founding Date
Founding Date
2010
Founding Date
2008
Founding Date
1998
Type
Type
Private
Type
Public
Type
Public
Tags
Locations
Locations
Manchester, GB HQ
Bradford, GB
Locations
Durham, US HQ
Locations
Calgary, CA HQ
Calgary, CA
San Diego, US
Employees
Employees
N/A
Employees
17015% increase
Employees
28
Valuation ($)
Valuation ($)
N/A
Valuation ($)
377.2 m
Valuation ($)
93.9 m

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$82.5m (FY, 2023)
Revenue (est.)
N/A
Cost of goods
Cost of goods
N/A
Cost of goods
$7.2m (FY, 2023)
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
$75.3m (FY, 2023)
Gross profit
N/A
Net income
Net income
N/A
Net income
($48m) (FY, 2023)
Net income
($28.8m) (FY, 2025)

Funding

Total funding raised
Total funding raised
$ 1.1m
Total funding raised
$ 289.6m
Total funding raised
$ 24m
For sources of this data, please see the company profile

View Company Profiles

G1 Therapeutics
HQ
Durham, US
Employees
170↑ 15% increase

G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer.

View company
Oncolytics Biotech
HQ
Calgary, CA
Employees
28

Oncolytics Biotech is a company developing Pelareorep, an intravenously delivered immuno-oncolytic virus, used for the treatment of solid tumors and hematological malignancies.

View company